SI2152290T1 - Postopki za dajanje anti-IL-5 protiteles - Google Patents

Postopki za dajanje anti-IL-5 protiteles

Info

Publication number
SI2152290T1
SI2152290T1 SI200831253T SI200831253T SI2152290T1 SI 2152290 T1 SI2152290 T1 SI 2152290T1 SI 200831253 T SI200831253 T SI 200831253T SI 200831253 T SI200831253 T SI 200831253T SI 2152290 T1 SI2152290 T1 SI 2152290T1
Authority
SI
Slovenia
Prior art keywords
antibodies
methods
administering anti
administering
Prior art date
Application number
SI200831253T
Other languages
English (en)
Inventor
Bela Rajiv Patel
Deborah Smith
Debra J. Tompson
Parnian Zia-Amirhosseini
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SI2152290T1 publication Critical patent/SI2152290T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
SI200831253T 2007-04-30 2008-04-30 Postopki za dajanje anti-IL-5 protiteles SI2152290T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91483307P 2007-04-30 2007-04-30
US99071507P 2007-11-28 2007-11-28
PCT/US2008/062015 WO2008134721A1 (en) 2007-04-30 2008-04-30 Methods for administering anti-il-5 antibodies
EP08747188.4A EP2152290B1 (en) 2007-04-30 2008-04-30 Methods for administering anti-il-5 antibodies

Publications (1)

Publication Number Publication Date
SI2152290T1 true SI2152290T1 (sl) 2014-09-30

Family

ID=39926128

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831253T SI2152290T1 (sl) 2007-04-30 2008-04-30 Postopki za dajanje anti-IL-5 protiteles

Country Status (12)

Country Link
US (5) US20100086554A1 (sl)
EP (4) EP2152310A4 (sl)
JP (6) JP2010526087A (sl)
CY (1) CY1115456T1 (sl)
DK (1) DK2152290T3 (sl)
ES (1) ES2492943T3 (sl)
HR (1) HRP20140789T1 (sl)
LT (1) LTC2152290I2 (sl)
PL (1) PL2152290T3 (sl)
PT (1) PT2152290E (sl)
SI (1) SI2152290T1 (sl)
WO (2) WO2008134721A1 (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152310A4 (en) * 2007-04-30 2010-05-26 Glaxosmithkline Llc METHODS OF ADMINISTERING ANTI-IL-5 ANTIBODIES
US9834600B2 (en) * 2008-03-28 2017-12-05 Glaxosmithkline Llc Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
TWI666447B (zh) 2010-12-16 2019-07-21 建南德克公司 關於ｔｈ２抑制作用之診斷及治療
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015061441A1 (en) 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
SG11201606870XA (en) 2014-02-21 2016-09-29 Genentech Inc Anti-il-13/il-17 bispecific antibodies and uses thereof
MX2017011486A (es) 2015-03-16 2018-06-15 Genentech Inc Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
MA42692A (fr) 2015-08-24 2018-07-04 Glaxosmithkline Ip No 2 Ltd Compositions biopharmaceutiques
AU2018273174B2 (en) 2017-05-26 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions and related methods
JP7295038B2 (ja) 2017-06-06 2023-06-20 グラクソスミスクライン エルエルシー 小児患者のための生物薬剤組成物及び方法
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
CA3226165A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
WO2023091608A2 (en) * 2021-11-18 2023-05-25 Memorial Sloan-Kettering Cancer Center Methods for treating anti-cancer drug-related skin rashes using benralizumab

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
IT1237881B (it) 1989-12-12 1993-06-18 Fast Spa Struttura a profilo complesso, applicabile su apparecchi agitatori, per il bloccaggio di barattoli di vernice, aventi coperchi comunque diversificati
CA2129445A1 (en) 1992-02-06 1993-08-07 Chuan-Chu Chou Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
WO1996021000A2 (en) 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US5696323A (en) * 1996-06-25 1997-12-09 Alliedsignal, Inc. Two bar resonant beam Coriolis rate sensor
US6248723B1 (en) * 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US5858089A (en) * 1997-08-26 1999-01-12 Martinovic; Zoran Corn buttering tool
ES2292210T3 (es) * 1997-10-22 2008-03-01 Mayo Foundation For Medical Education And Research Uso de agentes antifungicos para el tratamiento topico de mucositis inducida por hongos.
WO2003085089A2 (en) * 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
EP2152310A4 (en) * 2007-04-30 2010-05-26 Glaxosmithkline Llc METHODS OF ADMINISTERING ANTI-IL-5 ANTIBODIES
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
JP5035153B2 (ja) * 2008-07-14 2012-09-26 市光工業株式会社 車両用灯具

Also Published As

Publication number Publication date
HRP20140789T1 (hr) 2014-10-10
EP2152310A2 (en) 2010-02-17
US20100086547A1 (en) 2010-04-08
EP2152290A1 (en) 2010-02-17
WO2008134724A3 (en) 2009-02-12
US20200040073A1 (en) 2020-02-06
CY1115456T1 (el) 2017-01-04
ES2492943T3 (es) 2014-09-10
LTC2152290I2 (lt) 2018-12-27
EP2152310A4 (en) 2010-05-26
EP2777710A1 (en) 2014-09-17
JP2017036296A (ja) 2017-02-16
JP2020019781A (ja) 2020-02-06
EP2152290A4 (en) 2010-06-02
JP2010526087A (ja) 2010-07-29
US20180022799A1 (en) 2018-01-25
JP2018158934A (ja) 2018-10-11
US20100086554A1 (en) 2010-04-08
WO2008134721A1 (en) 2008-11-06
DK2152290T3 (da) 2014-08-18
JP2010526088A (ja) 2010-07-29
PL2152290T3 (pl) 2014-11-28
EP2606906A1 (en) 2013-06-26
US20160096886A1 (en) 2016-04-07
EP2152290B1 (en) 2014-06-04
LTPA2016005I1 (lt) 2018-11-12
PT2152290E (pt) 2014-09-03
WO2008134724A2 (en) 2008-11-06
JP2015028042A (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
EP2152290A4 (en) METHOD FOR THE ADMINISTRATION OF ANTI-IL-5 ANTIBODIES
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
HRP20130320T1 (en) Anti-myostatin antibodies
GB0708002D0 (en) Antibodies
HK1138790A1 (en) Anti-sclerostin antibodies
PL2195026T3 (pl) Przeciwciała przeciw sklerostynie
IL194995A0 (en) Modified humanised anti-interleukin-18 antibodies
EP2350655A4 (en) METHODS OF USING ANTIBODIES AND THEIR ANALOGUES
HK1136970A1 (en) Penta-specific antibody
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
HK1153502A1 (en) Anti-bst2 antibody bst2
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
IL197937A0 (en) Antibodies to lymphotoxin-alpha
GB0718737D0 (en) Antibodies
EP2198055A4 (en) HUMANIZED PAI-1 ANTIBODIES
GB0815788D0 (en) Therapeutic antibodies
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
ZA200902346B (en) Antibodies to lymphotoxin-alpha
GB0724185D0 (en) Antibodies
GB0607376D0 (en) Antibodies
GB0606276D0 (en) Antibodies
GB0619768D0 (en) Pharmaceutical composition comprising antibodies